Getting a denial for residential treatment or an intensive outpatient program (IOP) can feel disorienting, especially when treatment planning is already time-sensitive. In many cases, the denial letter uses phrases like “not medically necessary,” “wrong level of care,” “not covered,” or “out-of-network,” without fully explaining how the decision was made.
The good news is that a denial is not always the end of the road. In general terms, health plans often have formal appeal processes, and federal parity laws may offer additional support when a plan applies stricter barriers to substance use disorder care than it applies to medical or surgical care. The appeal process can also move quickly in urgent situations. According to HealthCare.gov, most people have 180 days to file an internal appeal, and an expedited pathway may be available when waiting could seriously jeopardize life, health, or the ability to regain maximum function. The U.S. Department of Labor similarly explains that many plan members can pursue external review after internal appeals are exhausted, often within 4 months of the final denial (Department of Labor).
In this post you’ll learn how denials for residential or IOP substance use treatment often happen, what documents may matter most, how parity and medical-necessity issues often overlap, and how an attorney may help evaluate whether the denial rests on legally questionable reasoning. If you want a broader overview of how these disputes fit into the larger insurance landscape, this guide on insurance denials for substance use treatment and parity issues adds useful background.
<aside> 💡 Scroll to the bottom for every post in this series.
</aside>
Substance use disorder treatment access remains a major national issue. SAMHSA reported that in 2024, 48.4 million people age 12 or older had a substance use disorder in the past year, yet only about 19.3% of people who were classified as needing treatment received it (SAMHSA). When coverage is denied for a clinically recommended level of care, the gap between “treatment needed” and “treatment received” can widen even more.
That gap is one reason disputes over level of care can become so consequential. Residential treatment may involve 24-hour structured services, while intensive outpatient treatment often provides a more concentrated non-residential level of care. The American Society of Addiction Medicine (ASAM) describes a continuum of care that includes outpatient, intensive outpatient, residential, and inpatient settings, with placement driven by multidimensional clinical assessment rather than a one-size-fits-all rule. When an insurer denies a request by saying outpatient is enough, or that residential is no longer appropriate, the core disagreement is often about clinical fit, safety, and the evidence supporting a particular level of care.
In appeal terms, these cases often turn on whether the plan agrees with the provider’s assessment of the appropriate level of care.
Residential treatment generally involves a structured setting with around-the-clock support. Depending on the clinical model, residential care can address relapse risk, unstable recovery environments, co-occurring mental health needs, medical monitoring, or repeated treatment failure at lower levels of care. ASAM’s criteria framework includes multiple residential levels and emphasizes matching care to patient needs through a multidimensional assessment process (ASAM).
Intensive outpatient programs usually allow the person to live at home while receiving frequent, structured treatment services several days per week. In some cases, IOP is used as a step-down from residential care. In others, it functions as the initial level of care when symptoms, relapse risk, and environmental factors indicate that ordinary outpatient treatment is not enough.
A plan may deny coverage because it claims: